Financials in USD. Standardized financial statements.
A compact view of how iTeos Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue? | $35.00M | $12.60M | $267.63M | $344.77M | $0 | $0 | $0 |
| Revenue Growth? | +177.9% | -95.3% | -22.4% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $1.24M | $898,000 | $813,000 | $615,000 | $535,000 | $611,000 | $505,000 |
| Gross Profit? | $33.76M | $11.70M | $266.82M | $344.16M | -$535,000 | -$611,000 | -$505,000 |
| Gross Margin? | +96.5% | +92.9% | +99.7% | +99.8% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $193.29M | $162.80M | $140.49M | $99.26M | $44.70M | $23.27M | $17.82M |
| Operating Income? | -$159.53M | -$151.10M | $126.32M | $244.90M | -$45.24M | -$28.05M | -$21.50M |
| EBITDA? | -$121.82M | -$111.66M | $148.38M | $257.08M | -$37.84M | -$22.51M | -$17.48M |
| Income Before Tax | -$120.34M | -$109.03M | $148.74M | $256.46M | -$38.09M | -$22.34M | -$18.05M |
| Income Tax Expense | $14.07M | $3.61M | $52.08M | $41.94M | -$57,000 | $119,000 | $11,000 |
| Net Income? | -$134.41M | -$112.64M | $96.65M | $214.52M | -$38.03M | -$22.45M | -$18.06M |
| EPS? | $-3.32 | $-3.15 | $2.72 | $6.10 | $-1.24 | $-2.27 | $-2.40 |
| Diluted EPS? | $-3.32 | $-3.15 | $2.56 | $5.68 | $-1.24 | $-2.27 | $-2.40 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality